Clarametyx Biosciences’ Post

Clarametyx COO Dr. Veronica Hall shares her perspective on how the newly announced agreement with CARB-X helps to support our platform strategy and accelerate development in an area of high unmet need in infectious disease. https://lnkd.in/em6azQ85

  • text
Michael Abram

Translational Research | Product Development | Strategic Partnerships | Collaboration Management | External Innovation | Infectious Diseases R&D (antivirals, mAbs, and vaccines)

2mo

Congratulations Veronica and the Clarametyx team on this exciting agreement with CARB-X!

Like
Reply
Diana Ororbia-Knapton

Director,Government Contracts Accounting at Emergent BioSolutions

2mo

Congrats!Veronica! All the best!

Like
Reply

Inspiring! Great work!!

Like
Reply
Lei Lei Sengchanthalangsy

High performing leader with proven results in successfully managing cross-functional teams in drug development, business strategy, and operations

2mo

Congrats Veronica!

Like
Reply

Congrats to Clarametyx. Full speed ahead.

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics